Artificial intelligence is progressively establishing itself as a major driver of transformation in the pharmaceutical industry. From molecule discovery to pharmacovigilance, including the optimization of clinical trials and the control of industrial processes, AI models now contribute to decisions that can have a direct impact on patient safety and the quality of medicines. In such a highly regulated environment, their validation cannot be treated as a mere technical exercis